24 related articles for article (PubMed ID: 20096226)
1. Immunosuppressive protocols after laryngeal transplantation: a systematic review.
Baudouin R; Von Tokarski F; Rigal T; Crambert A; Hertig A; Hans S
Acta Otolaryngol; 2024 Mar; 144(3):243-249. PubMed ID: 38662869
[TBL] [Abstract][Full Text] [Related]
2. Trends in Surgical Research in Head and Neck Cancer.
Tolstonog G; Simon C
Curr Treat Options Oncol; 2017 Jun; 18(6):38. PubMed ID: 28550447
[TBL] [Abstract][Full Text] [Related]
3. Decoy NF-kappaB fortified immature dendritic cells maintain laryngeal allograft integrity and provide enhancement of regulatory T cells.
Lott DG; Dan O; Lu L; Strome M
Laryngoscope; 2010 Jan; 120(1):44-52. PubMed ID: 19877191
[TBL] [Abstract][Full Text] [Related]
4. Laryngeal transplantation in the setting of cancer: a rat model.
Shipchandler TZ; Lorenz RR; Lee WT; Teker AM; Dan O; Strome M
Laryngoscope; 2008 Dec; 118(12):2166-71. PubMed ID: 18948827
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
6. Induction with T-cell receptor antibody leads to long-term laryngeal allograft function.
Knott PD; Dan O; Strome M
Am J Otolaryngol; 2008; 29(6):398-402. PubMed ID: 19144301
[TBL] [Abstract][Full Text] [Related]
7. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
Cai Y; Tang XD; Zhou PJ
Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
[TBL] [Abstract][Full Text] [Related]
8. Long-term laryngeal allograft survival using low-dose everolimus.
Lott DG; Dan O; Lu L; Strome M
Otolaryngol Head Neck Surg; 2010 Jan; 142(1):72-8. PubMed ID: 20096226
[TBL] [Abstract][Full Text] [Related]
9. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
10. Everolimus: efficacy and safety in cardiac transplantation.
Schaffer SA; Ross HJ
Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
[TBL] [Abstract][Full Text] [Related]
11. Anti-αβ-T-cell receptor antibodies in the setting of laryngeal transplantation.
Strome M; Lott DG
Immunotherapy; 2010 Nov; 2(6):835-45. PubMed ID: 21091115
[TBL] [Abstract][Full Text] [Related]
12. Laryngeal transplantation in 2005: a review.
Birchall MA; Lorenz RR; Berke GS; Genden EM; Haughey BH; Siemionow M; Strome M
Am J Transplant; 2006 Jan; 6(1):20-6. PubMed ID: 16433752
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
